Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids
CONCLUSIONS: There were considerable differences in OUD symptom patterns and substance use treatment among individuals who misused opioids. The findings indicate a substantial unmet need for OUD treatment and point to patterns of heterogeneity within OUD that can inform development of treatment programs.PMID:38414666 | PMC:PMC10897812 | DOI:10.1016/j.dadr.2024.100220 (Source: Pharmacological Reports)
Source: Pharmacological Reports - February 28, 2024 Category: Drugs & Pharmacology Authors: Emily A Miller Angela M DeVeaugh-Geiss Howard D Chilcoat Source Type: research
Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids
CONCLUSIONS: There were considerable differences in OUD symptom patterns and substance use treatment among individuals who misused opioids. The findings indicate a substantial unmet need for OUD treatment and point to patterns of heterogeneity within OUD that can inform development of treatment programs.PMID:38414666 | PMC:PMC10897812 | DOI:10.1016/j.dadr.2024.100220 (Source: Pharmacological Reports)
Source: Pharmacological Reports - February 28, 2024 Category: Drugs & Pharmacology Authors: Emily A Miller Angela M DeVeaugh-Geiss Howard D Chilcoat Source Type: research
Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids
CONCLUSIONS: There were considerable differences in OUD symptom patterns and substance use treatment among individuals who misused opioids. The findings indicate a substantial unmet need for OUD treatment and point to patterns of heterogeneity within OUD that can inform development of treatment programs.PMID:38414666 | PMC:PMC10897812 | DOI:10.1016/j.dadr.2024.100220 (Source: Pharmacological Reports)
Source: Pharmacological Reports - February 28, 2024 Category: Drugs & Pharmacology Authors: Emily A Miller Angela M DeVeaugh-Geiss Howard D Chilcoat Source Type: research
Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids
CONCLUSIONS: There were considerable differences in OUD symptom patterns and substance use treatment among individuals who misused opioids. The findings indicate a substantial unmet need for OUD treatment and point to patterns of heterogeneity within OUD that can inform development of treatment programs.PMID:38414666 | PMC:PMC10897812 | DOI:10.1016/j.dadr.2024.100220 (Source: Pharmacological Reports)
Source: Pharmacological Reports - February 28, 2024 Category: Drugs & Pharmacology Authors: Emily A Miller Angela M DeVeaugh-Geiss Howard D Chilcoat Source Type: research
Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids
CONCLUSIONS: There were considerable differences in OUD symptom patterns and substance use treatment among individuals who misused opioids. The findings indicate a substantial unmet need for OUD treatment and point to patterns of heterogeneity within OUD that can inform development of treatment programs.PMID:38414666 | PMC:PMC10897812 | DOI:10.1016/j.dadr.2024.100220 (Source: Pharmacological Reports)
Source: Pharmacological Reports - February 28, 2024 Category: Drugs & Pharmacology Authors: Emily A Miller Angela M DeVeaugh-Geiss Howard D Chilcoat Source Type: research
Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer
Pharmacol Rep. 2024 Feb 22. doi: 10.1007/s43440-024-00568-7. Online ahead of print.ABSTRACTRenal cell carcinoma (RCC) arises from the tubular epithelial cells of the nephron. It has the highest mortality rate among urological cancers. There are no effective therapeutic approaches and no non-invasive biomarkers for diagnosis and follow-up. Thus, suitable novel biomarkers and therapeutic targets are essential for improving RCC diagnosis/prognosis and treatment. Circulating exosomes such as exosomal microRNAs (Exo-miRs) provide non-invasive prognostic/diagnostic biomarkers and valuable therapeutic targets, as they can be easi...
Source: Pharmacological Reports - February 22, 2024 Category: Drugs & Pharmacology Authors: Xiaodong Yu Zhongbo Du Pingyu Zhu Bo Liao Source Type: research
Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer
Pharmacol Rep. 2024 Feb 22. doi: 10.1007/s43440-024-00568-7. Online ahead of print.ABSTRACTRenal cell carcinoma (RCC) arises from the tubular epithelial cells of the nephron. It has the highest mortality rate among urological cancers. There are no effective therapeutic approaches and no non-invasive biomarkers for diagnosis and follow-up. Thus, suitable novel biomarkers and therapeutic targets are essential for improving RCC diagnosis/prognosis and treatment. Circulating exosomes such as exosomal microRNAs (Exo-miRs) provide non-invasive prognostic/diagnostic biomarkers and valuable therapeutic targets, as they can be easi...
Source: Pharmacological Reports - February 22, 2024 Category: Drugs & Pharmacology Authors: Xiaodong Yu Zhongbo Du Pingyu Zhu Bo Liao Source Type: research
Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer
Pharmacol Rep. 2024 Feb 22. doi: 10.1007/s43440-024-00568-7. Online ahead of print.ABSTRACTRenal cell carcinoma (RCC) arises from the tubular epithelial cells of the nephron. It has the highest mortality rate among urological cancers. There are no effective therapeutic approaches and no non-invasive biomarkers for diagnosis and follow-up. Thus, suitable novel biomarkers and therapeutic targets are essential for improving RCC diagnosis/prognosis and treatment. Circulating exosomes such as exosomal microRNAs (Exo-miRs) provide non-invasive prognostic/diagnostic biomarkers and valuable therapeutic targets, as they can be easi...
Source: Pharmacological Reports - February 22, 2024 Category: Drugs & Pharmacology Authors: Xiaodong Yu Zhongbo Du Pingyu Zhu Bo Liao Source Type: research
Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer
Pharmacol Rep. 2024 Feb 22. doi: 10.1007/s43440-024-00568-7. Online ahead of print.ABSTRACTRenal cell carcinoma (RCC) arises from the tubular epithelial cells of the nephron. It has the highest mortality rate among urological cancers. There are no effective therapeutic approaches and no non-invasive biomarkers for diagnosis and follow-up. Thus, suitable novel biomarkers and therapeutic targets are essential for improving RCC diagnosis/prognosis and treatment. Circulating exosomes such as exosomal microRNAs (Exo-miRs) provide non-invasive prognostic/diagnostic biomarkers and valuable therapeutic targets, as they can be easi...
Source: Pharmacological Reports - February 22, 2024 Category: Drugs & Pharmacology Authors: Xiaodong Yu Zhongbo Du Pingyu Zhu Bo Liao Source Type: research
Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience
CONCLUSIONS: Active GO treatment with high-dose systemic GCs is not associated with serious side effects. Hyperglycemia is the most common steroid-induced complication.PMID:38273183 | PMC:PMC10830746 | DOI:10.1007/s43440-023-00567-0 (Source: Pharmacological Reports)
Source: Pharmacological Reports - January 25, 2024 Category: Drugs & Pharmacology Authors: Nadia Sawicka-Gutaj Dawid Gruszczy ński Natalia Zawalna Kacper Nijakowski Agnieszka Skiba Mateusz Pochylski Jerzy Sowi ński Marek Rucha ła Source Type: research
Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience
CONCLUSIONS: Active GO treatment with high-dose systemic GCs is not associated with serious side effects. Hyperglycemia is the most common steroid-induced complication.PMID:38273183 | PMC:PMC10830746 | DOI:10.1007/s43440-023-00567-0 (Source: Pharmacological Reports)
Source: Pharmacological Reports - January 25, 2024 Category: Drugs & Pharmacology Authors: Nadia Sawicka-Gutaj Dawid Gruszczy ński Natalia Zawalna Kacper Nijakowski Agnieszka Skiba Mateusz Pochylski Jerzy Sowi ński Marek Rucha ła Source Type: research
Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience
CONCLUSIONS: Active GO treatment with high-dose systemic GCs is not associated with serious side effects. Hyperglycemia is the most common steroid-induced complication.PMID:38273183 | PMC:PMC10830746 | DOI:10.1007/s43440-023-00567-0 (Source: Pharmacological Reports)
Source: Pharmacological Reports - January 25, 2024 Category: Drugs & Pharmacology Authors: Nadia Sawicka-Gutaj Dawid Gruszczy ński Natalia Zawalna Kacper Nijakowski Agnieszka Skiba Mateusz Pochylski Jerzy Sowi ński Marek Rucha ła Source Type: research
Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience
CONCLUSIONS: Active GO treatment with high-dose systemic GCs is not associated with serious side effects. Hyperglycemia is the most common steroid-induced complication.PMID:38273183 | PMC:PMC10830746 | DOI:10.1007/s43440-023-00567-0 (Source: Pharmacological Reports)
Source: Pharmacological Reports - January 25, 2024 Category: Drugs & Pharmacology Authors: Nadia Sawicka-Gutaj Dawid Gruszczy ński Natalia Zawalna Kacper Nijakowski Agnieszka Skiba Mateusz Pochylski Jerzy Sowi ński Marek Rucha ła Source Type: research
Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience
CONCLUSIONS: Active GO treatment with high-dose systemic GCs is not associated with serious side effects. Hyperglycemia is the most common steroid-induced complication.PMID:38273183 | PMC:PMC10830746 | DOI:10.1007/s43440-023-00567-0 (Source: Pharmacological Reports)
Source: Pharmacological Reports - January 25, 2024 Category: Drugs & Pharmacology Authors: Nadia Sawicka-Gutaj Dawid Gruszczy ński Natalia Zawalna Kacper Nijakowski Agnieszka Skiba Mateusz Pochylski Jerzy Sowi ński Marek Rucha ła Source Type: research
Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience
CONCLUSIONS: Active GO treatment with high-dose systemic GCs is not associated with serious side effects. Hyperglycemia is the most common steroid-induced complication.PMID:38273183 | PMC:PMC10830746 | DOI:10.1007/s43440-023-00567-0 (Source: Pharmacological Reports)
Source: Pharmacological Reports - January 25, 2024 Category: Drugs & Pharmacology Authors: Nadia Sawicka-Gutaj Dawid Gruszczy ński Natalia Zawalna Kacper Nijakowski Agnieszka Skiba Mateusz Pochylski Jerzy Sowi ński Marek Rucha ła Source Type: research
